Compare OGI & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OGI | SGMT |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.5M | 169.4M |
| IPO Year | 2015 | 2021 |
| Metric | OGI | SGMT |
|---|---|---|
| Price | $1.40 | $7.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $26.13 |
| AVG Volume (30 Days) | 754.6K | ★ 2.5M |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | $20.10 | N/A |
| Revenue Next Year | $13.92 | N/A |
| P/E Ratio | $13.91 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.10 | $3.15 |
| 52 Week High | $2.24 | $11.41 |
| Indicator | OGI | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 49.60 | 63.68 |
| Support Level | $1.30 | $6.61 |
| Resistance Level | $1.72 | $9.11 |
| Average True Range (ATR) | 0.08 | 0.68 |
| MACD | -0.01 | 0.14 |
| Stochastic Oscillator | 22.22 | 61.26 |
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.